Compounded GLP-1s
Compounded GLP-1s are pharmacy-prepared versions of medications like semaglutide and tirzepatide — compounded broadly during the branded drugs’ FDA shortages, and since operating through the patient-specific pathway: preparations tailored to an individual patient’s documented clinical needs.
- Compounded broadly during the 2022–2024 branded shortages
- Shortages resolved in 2024–2025; the broad window closed
- The patient-specific pathway continues, built on documented clinical need
- Documentation, sourcing diligence, and claims discipline are the operator’s job
How the compounding window opened and closed
When branded semaglutide and tirzepatide entered FDA shortage, compounding rules allowed pharmacies to prepare versions of them broadly — and compounded GLP-1s made medical weight care affordable at national scale. When the FDA declared the shortages resolved (tirzepatide in late 2024, semaglutide in early 2025), that broad window closed, and the category returned to compounding’s standing rule: preparations must serve an individual patient’s documented clinical needs rather than copy a commercially available product.
The patient-specific pathway is where programs operate today: individualized formulations, strengths, and combinations supported by a clinician’s documented determination. Run with strong documentation, sourcing diligence, and careful claims, it is standard compounding practice — the same pathway hormones and other customized therapies have always used.
What this means for weight-care programs
Programs adapted along two lines: tightening the clinical documentation behind compounded offerings, and adding branded products through the manufacturers’ direct cash channels where they fit. The durable lesson: rules in this category move, so catalog flexibility — the ability to adjust products without rebuilding flows — is the strongest position an operator can hold.
Era by era
| Era | What was lawful | What programs did |
|---|---|---|
| Shortage era (2022–2024) | Broad compounding under the shortage provision | Built affordable national weight-care programs |
| Wind-down (2024–2025) | Grace periods for 503A and 503B compounders | Transitioned patients and tightened documentation |
| Today | Patient-specific pathway + branded products | Run both, matched per patient by clinicians |
The pharmacies behind the programs
Compounded GLP-1 programs run on 503A compounding pharmacies — and not every 503A qualifies. GLP-1s are sterile injectables, so the pharmacy needs USP <797> sterile compounding capability, semaglutide or tirzepatide API from FDA-registered suppliers with per-lot certificates of analysis, and non-resident licenses covering every state the program ships into. Programs at scale run two or more pharmacy partners so a licensure hiccup or capacity crunch in one never becomes a missed refill for patients.
The pharmacy relationship is also where the patient-specific pathway becomes real: the prescription arrives with the clinician’s individualized rationale, and the pharmacy compounds to that prescription — formulation, strength, and combination reflecting the documented need. A strong pharmacy partner is a compliance asset, not just a vendor.
Compliance handled, so you can build
Lithos runs the clinicians, pharmacies, and 50-state rules behind your care program — one API.
Frequently asked questions
Can a program still offer compounded semaglutide?
Yes, through the patient-specific pathway: prescriptions reflecting an individual patient’s documented clinical needs. The discipline that matters is documentation — every prescription should carry the individualized rationale in the chart.
Why were compounded GLP-1s so cheap?
Compounding pharmacies priced the molecule without the brand’s R&D and market position — which is why the model only existed inside the shortage exception.
How do branded direct channels fit in?
Manufacturer cash-pay channels sit alongside compounded offerings in many programs — clinicians match patients to the right product, and diversity across products makes the catalog resilient.